both INH plus RIF and INH alone have been tried,
primarily in Europe, with no reported increase in
mortality (21% vs 24%, respectively).122
When providing care for lung transplant recipients, an extremely high-risk population, infections
must be high on the differential diagnosis with every
complaint. Aside from the infections discussed in
this article, one must be mindful about how immune
dysregulation can lead to chronic rejection of lung
recipients’ allografts. Antibacterial agents, antifungal
agents and antiviral agents are available to aid in
treating a broad range of infectious complications.
This vulnerable population is at increased risk for a
number of major infections, and in many instances
it is appropriate to provide prophylaxis against the
most dangerous culprits. Understanding the above
infections, timing of presentation, and different treatment strategies, the goals of management are to
prevent infections when possible, identify and treat
infections early, limit adverse effects of the treatments, and prevent the downstream consequences
of infectious episodes.
1. Yusen RD, Christie JD, Edwards LB, et al. The Registry
of the International Society for Heart and Lung Transplantation: thirtieth adult lung and heart-lung transplant
report--2013; focus theme: age. J Heart Lung Transplant
2. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.
J Heart Lung Transplant 2002;21:297–310.
3. Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft
colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans
syndrome in recipients with cystic fibrosis. Respir Med
4. Vos R, Vanaudenaerde BM, Geudens N, et al. Pseudo-monal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J
5. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis
obliterans syndrome. Am J Transplant 2009;9:1903–11.
6. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med
7. Campos S, Caramori M, Teixeira R, et al. Bacterial and
fungal pneumonias after lung transplantation. Transplant
8. Duarte AG, Myers AC. Cough reflex in lung transplant recipients. Lung 2012;190:23–7.
9. Wang F, Winter JB, Dam M, et al. Influence of interrupted
pulmonary lymph drainage on antibody responses in hilar-stripped lungs. J Heart Lung Transplant 1992;4:S215–220.
10. Kshettry VR, Kroshus TJ, Hertz MI, et al. Early and late
airway complications after lung transplantation: incidence
and management. Ann Thorac Surg 1997;63:1576–83.
11. Van Raemdonck D, Neyrinck A, Verleden GM, et al. Lung
donor selection and management. Proc Am Thorac Soc
12. Riou B, Guesde R, Jacquens Y, et al. Fiberoptic bronchoscopy in brain-dead organ donors. Am J Respir Crit Care
13. Hsieh H, Bishop MJ, Kubilis PS, et al. Pneumonia following
closed head injury. Am Rev Respir Dis 1992;146:290– 4.
14. Ruiz I, Gavaldà J, Monforte V, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 2006;6:178–82.
15. Bonvillain RW, Valentine VG, Lombard G, et al. Postoperative infections in cystic fibrosis and non-cystic fibrosis
patients after lung transplantation. J Heart Lung Transplant
16. Lipuma JJ. The changing microbial epidemiology in cystic
fibrosis. Clin Microbiol Rev 2010;23:299–323.
17. Snell GI, de Hoyos A, Krajden M, et al. Pseudomonas
cepacia in lung transplant recipients with cystic fibrosis.
18. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact
of burkholderia infection on lung transplantation in cystic
fibrosis. Am J Respir Crit Care Med 2008;178:363–71.
19. Alexander BD, Petzold EW, Reller LB, et al. Survival after
BOARD REVIEW QUESTIONS
Test your knowledge of this topic.
Go to www.turner-white.com and select Pulmonary Disease
from the drop-down menu of specialties.